RRMS

Irisin Hormone May Underlie Benefits of Aerobic Exercise for RRMS

Six weeks of aerobic exercise led to benefits in cognition, fatigue, and depression among people with relapsing-remitting multiple sclerosis (RRMS), which may be due to increases in blood levels of a hormone called irisin, according to data from a randomized, controlled trial. “Considering the high prevalence of neuropsychiatric symptoms…

MS Doctors, Nurses in UK Struggle With Marking Transition to SPMS

Among healthcare providers in the U.K., considerable variation exists in marking the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS), a study based on interview responses reports. Neurologists and nurses with MS specialties also expressed a reluctance to label patients as having progressed to…

BCG Vaccine for TB Not Linked to MS Risk: Large Canadian Study

Getting the Bacillus Calmette-Guerin (BCG) vaccine to protect against tuberculosis (TB) — an immunization often given to infants and small children in countries where TB is common — does not decrease a person’s risk of developing multiple sclerosis (MS), according to a new study. “Within a large birth cohort…

Novantrone Lowers Relapses, Eases Disability in Highly Active RRMS

Initial treatment with Novantrone (mitoxantrone) can reduce the risk of relapses and worsening disability in people with highly active relapsing-remitting multiple sclerosis (RRMS), according to a 10-year study from France. “Our results support the short-term use of [Novantrone], followed by a maintenance therapy for patients with early highly…

Worsening Disability in Absence of Relapses ‘Underestimated’ in MS

A substantial amount of disability worsening happens independently of relapses in people with multiple sclerosis (MS), including those in earlier stages of relapsing-remitting disease, a study in a large patient database reported. While its findings “confirm relapses contribute to the accumulation of disability, primarily early in multiple sclerosis,” data…

Lyrics and Loving Myself: Rediscovering My Lost Voice

“Most of the time, the greatest rewards come from doing the things that scare you the most. Maybe you’ll get everything you wish for. Maybe you’ll get more than you ever could have imagined. Who knows where life will take you? The road is long, and in the end, the…

Ketogenic Diet Eases Symptoms, Aids Life Quality in Small RRMS Study

A short-term ketogenic diet, which dramatically cuts carbohydrate consumption, is safe and results in significant improvements in people with relapsing-remitting multiple sclerosis (RRMS), a small study in patients reported. “Our study provides evidence that a ketogenic diet is safe and beneficial, reducing some symptoms for people with MS, when…

#ACTRIMS2022 – Blood NfL Levels May Help Quantify Relapse Severity

Measuring levels of the neurofilament light chain (NfL) protein in blood may be a way to “quantify” relapse severity and predict future disability in people with relapsing-remitting multiple sclerosis (RRMS). “Higher [blood] NfL levels during periods of active inflammation predicted more [brain] atrophy,” researchers wrote in an abstract titled…

Endurance Sports Inspire Young Frenchman With RRMS

Sports was a huge part of Armand Thoinet’s life, and when he was diagnosed with relapsing-remitting multiple sclerosis (MS) one week before his 19th birthday, that life turned upside down. He could no longer engage in activities that mattered greatly to him, such as rugby, tennis, and skiing. “I…

After Pregnancy, Women Show More Brain Lesions, Volume Loss

Women with relapsing-remitting multiple sclerosis (RRMS) have more brain lesions and accelerated brain volume loss (BVL) after pregnancy compared with pre-pregnancy measurements, recent data showed. Brain lesions in the early postpartum period — the first months following childbirth — were associated with a higher risk of worsened disability and relapse…

Acthar Gel May Help RRMS Patients Who Fail Corticosteroids

Acthar Gel (repository corticotropin injection) may be useful for managing disease relapses in people with relapsing-remitting multiple sclerosis (RRMS) who fail to respond to treatment with corticosteroids, according to results from a small clinical trial. The study, “Results from a multicenter, randomized, double-blind, placebo-controlled study…

Regular Eye Screening Vital for MS Patients, Study Finds

Visual disturbances are common in people with multiple sclerosis (MS), particularly among those with secondary progressive MS (SPMS), longer disease duration, and worse disability status, a new study has found. Yet, “visual complaints may occur in people with all types of MS, anytime along the disease course, and…

Imaging of Retina Can Help in Monitoring Nerve Cell Damage in MS

An imaging technique called optical coherence tomography (OCT) could be useful for monitoring nervous system damage in people with multiple sclerosis (MS), especially early on in the disease, a study in patients reports. The study, “Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study,”…

Report: Tecfidera, Aubagio Preferred RRMS Treatments in Canada

Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments for managing relapsing-remitting multiple sclerosis (RRMS) in Canada, according to a report from Spherix Global Insights. The report was part of Spherix’s RealTime Dynamix: Multiple Sclerosis (Canada) service, which collects data on market trends of MS…

Worsening of Disability Evident in Older Patients Who Stop DMTs

While older multiple sclerosis (MS) patients whose conditions are stable commonly stop using disease-modifying therapies (DMTs), a study indicates this decision can shortly lead to a marked disease worsening in a substantial portion of them. “Our results raise important questions about the accepted practice of discontinuing medications once MS…

1st Patient Enrolled in ENSURE Trials of IMU-838 in RRMS

Immunic Therapeutics has enrolled the first participant in its Phase 3 ENSURE clinical trial program, which is testing the company’s investigational treatment IMU-838 (vidofludimus calcium) in people with relapsing-remitting multiple sclerosis (RRMS). “Enrollment of the first patient in ENSURE … marks an important inflection point for Immunic as we…

Long-term Supplement Use May Improve Gait, Strength in RRMS

Long-term use of a high-dose nutritional supplement containing specific antioxidant vitamins and omega-3 and omega-6 fatty acids may boost walking performance and other measures of functional capacity in people with relapsing-remitting multiple sclerosis (RRMS), a new study found. The study, “The Effects of Specific Omega-3 and…

Vumerity Approved for RRMS in European Union

The oral medication Vumerity (diroximel fumarate) has been approved by the European Commission to treat adults with relapsing-remitting multiple sclerosis (RRMS). “This approval is a significant step forward in improving treatment adherence for people living with relapsing MS, which can make a meaningful difference on treatment…

Cerebellar Lesions in RRMS Linked to Worsening Manual Dexterity

The number of lesions affecting the cerebellum — a brain region responsible for coordinating voluntary movements and motor skills such as balance, coordination, and posture — predicts manual dexterity getting worse in people with relapsing-remitting multiple sclerosis (RRMS), according to a retrospective analysis. The study, “Cerebellar pathology and…

Ocrevus Benefited RRMS Patients Who Responded Poorly to DMTs

Most relapsing-remitting multiple sclerosis (RRMS) patients switching to Ocrevus (ocrelizumab) following suboptimal responses to other disease-modifying therapies (DMTs) show no evidence of disease activity, according to final two-year data from the European-based CASTING Phase 3b trial. These clinical benefits, which entail no relapses or disease progression and no…